Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Evolving Therapeutic Strategies with Next-Generation Anti-VEGF Agents in Retinal | Ophthalmology Times
This segment examines how the advent of higher-dose and dual-pathway anti-VEGF agents has reshaped treatment strategies for retinal vascular diseases. The discussion underscores how aflibercept 8 mg and faricimab have improved anatomic outcomes and extended dosing intervals, offering meaningful—though patient-specific—reductions…
Managing challenging pterygium removal: Amniotic membrane grafting strategies | Ophthalmology Times
(Image Credit: AdobeStock/Sangiao_Photography) Pterygium is a common ocular surface disorder characterized by a fibrovascular growth originating from the conjunctiva that extends onto the adjacent cornea (Figure).1 Its prevalence varies considerably across geographic regions. Because prolonged sun exposure is the main…
Argenx discontinues phase 3 UplighTED trials of efgartigimod SC in thyroid eye disease | Ophthalmology Times
(Image Credit: AdobeStock/SnapVault) Argenx SE has discontinued the phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED). According to the company, the trial is being discontinued based…
Aviceda Therapeutics reports positive phase 2b SIGLEC results for AVD-104 in geographic atrophy | Ophthalmology Times
(Image Credit: AdobeStock/9dreamstudio) Aviceda Therapeutics has released topline results from its phase 2b study, SIGLEC, evaluating AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). AVD-104 is a polysialic acid-coated nanoparticle in which the polysialic acid…
Advantages of Neurogenic Stimulation and Identifying Ideal Dry Eye Candidates for Acoltremon | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
The Role of TRPM8 Agonists in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA | Ophthalmology Times
(Image Credit: AdobeStock) Inflammasome Therapeutics has completed enrollment in a multicenter phase 2 dose-ranging trial (NCT06164587) for its dual inflammasome inhibitor, K8, for geographic atrophy (GA). K8 is a member of a new class of inflammasome-inhibiting drugs called Kamuvudines. They…
FDA approves Amneal Pharmaceuticals’ cyclosporine ophthalmic emulsion 0.05%. | Ophthalmology Times
The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ cyclosporine ophthalmic emulsion 0.05%, which is is the generic equivalent of RESTASIS 0.05%, a registered trademark of Allergan, an AbbVie company. Cyclosporine ophthalmic emulsion 0.05% is a topical immunomodulator…
The Art and Science of Presbyopia Correction: Navigating the IOL Patient Journey | Ophthalmology Times
Presbyopia-correcting IOLs have undergone a dramatic transformation in recent years. The once-limited options for patients seeking reduced spectacle dependence after cataract surgery have evolved into a diverse and sophisticated array of IOL technologies, including trifocal, extended depth-of-focus (EDOF), small-aperture, light-adjustable,…
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved in Canada | Ophthalmology Times
(Image Credit: AdobeStock/platinumArt) Health Canada has approved Celltrion’s Eydenzelt, a biosimilar referencing Eylea (aflibercept 2 mg), in both vial and pre-filled syringe format, for the treatment of all indications approved for Eylea, which in the US include neovascular (wet) age-related…